Klin Farmakol Farm. 2019;33(4):35-38 | DOI: 10.36290/far.2019.030

Angiotensin converting enzyme inhibitors in nephrology

Věra Čertíková Chábová
Klinika nefrologie 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha

Angiotensin converting enzyme (ACE) inhibitors are antihypertensive drugs used also for treatment of heart failure and decrease of proteinuria in renal diseases. However, the renin-angiotensin-aldosterone system is very complex and there are more drugs with similar effects, such as angiotensin II receptor blockers. These drugs have less side effects and that is why they are preferred nowadays. This cannot change the fact that ACE inhibitors, beside blood pressure lowering, can slow down the rate of glomerular filtration loss and decrease the risk of cardiovascular complications and mortality. All guidelines for hypertension treatment list them as first choise option.

Keywords: renin‑angiotensin‑aldosterone system, ACE inhibitors, hypertension, chronic renal disease.

Published: January 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čertíková Chábová V. Angiotensin converting enzyme inhibitors in nephrology. Klin Farmakol Farm. 2019;33(4):35-38. doi: 10.36290/far.2019.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Messerli FH a kol. Angiotensin‑Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol 2018; 71: 1474-1482. Go to original source... Go to PubMed...
    2. SÚKL: Databáze léků (on line). (cit. 2019-08-05). Dostupný na www: http://www.sukl.cz/modules/medication/search.php
    3. Nehme A a kol. An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. J Cardiovasc Dev Dis 2019, Mar 29; 6(2). pii: E14. doi: 10.3390/jcdd6020014. Go to original source... Go to PubMed...
    4. Bavishi C, Bangalore S, Messerli FH. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction? Prog Cardiovasc Dis 2016; 59: 253-261. Go to original source... Go to PubMed...
    5. Trietley GS a kol. Clinical Inquiry: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? J Fam Pract 2017; 66: 257-263.
    6. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012; 12: CD004136. Go to original source... Go to PubMed...
    7. American Diabetes Association. 11. Microvascular Complications and Foot Care:. Diabetes Care 2019; 42: S124-S38.
    8. Lovshin JA a kol. Renin‑angiotensin‑aldosterone system activation in long‑standing type 1 diabetes. JCI Insight 2018; 3(1). pii: 96968. doi: 10.1172/jci.insight.96968 Go to original source... Go to PubMed...
    9. Čertíková Chábová V, Červenka L. The dilemma of dual renin‑angiotensin system blockade in chronic kidney disease: why beneficial in animal experiments but not in the clinic? Physiol Res 2017; 66: 181-192. Go to original source... Go to PubMed...
    10. Barrera‑Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int 2019; 96: 302-119. Go to original source... Go to PubMed...
    11. Beige J. Early Rapid Decline in Kidney Function as a Beneficial Sign After Starting Antihypertensive Medication. J Am Heart Assoc 2019; 8: e013145. Go to original source... Go to PubMed...
    12. Ohkuma T, Jun M, Rodgers A, et al. Acute Increases in Serum Creatinine After Starting Angiotensin‑Converting Enzyme Inhibitor‑Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension 2019; 73: 84-91. Go to original source... Go to PubMed...
    13. Bhandari S, Ives N, Brettell EA, et al. Multicentre randomized controlled trial of angiotensin‑converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP‑ACEi trial. Nephrol Dial Transplant 2016; 31: 255-261. Go to original source...
    14. Nehme A, Cerutti C, Dhaouadi N, et al. Atlas of tissue renin‑angiotensin‑aldosterone system in human: A transcriptomic meta‑analysis. Sci Rep 2015; 5: e10035. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.